The current investigation revealed the value of host modulation therapy with Omega-3FAs oral administration as adjunct to nonsurgical periodontal therapy in management of patients with periodontitis and type II diabetes, as it resulted in significant improvement of clinical periodontal parameters and glycemic control with the additional benefit of reducing both local and systemic chemerin levels a biomarker for cardiovascular risk. This evidence concerns the gene RARRES2 and type 2 diabetes mellitus.